Latest Hotspot

Abeona Therapeutics Reveals FDA Approval and Priority Review Provision for Pz-cel Biologics License Application (BLA)

1 December 2023
3 min read

Abeona Therapeutics Inc. has confirmed that the FDA has given priority review status to its Biologics License Application for pz-cel (prademagene zamikeracel), a proprietary therapy developed by the company. This autologous, COL7A1 gene-corrected epidermal sheet technology is specifically devised for treating those affected by recessive dystrophic epidermolysis bullosa.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成Under the legislation of the Prescription Drug User Fee Act, the FDA has aimed to take action by May 25, 2024. Currently, there are no plans by the FDA to organize an Advisory Committee discussion for the pz-cel application. 

Receiving the BLA priority review from the FDA emphasizes the severe lack of solutions for RDEB, and signifies the potential of pz-cel to make a significant difference for these patients,” commented Vish Seshadri, CEO of Abeona. “We are grateful to the FDA for their dedication and are eager to collaborate with them throughout the BLA assessment, aiming to bring this treatment to patients as rapidly as possible.”

The BLA is reinforced by clinical efficacy and safety outcomes from the crucial Phase 3 VIITAL™ study, as well as confirmatory evidence from a Phase 1/2a study. Both studies demonstrated that a single use of pz-cel on large and chronic wounds facilitated long-lasting wound healing and alleviated pain. 

The acknowledgment of the Priority Review status is a significant initial step for Abeona’s possibility of obtaining a Priority Review Voucher. Pz-cel (prademagene zamikeracel), an experimental autologous, COL7A1 gene-corrected epidermal sheets from Abeona, is under development at present for treating recessive dystrophic epidermolysis bullosa, a unique connective tissue disorder resulting from a defect in the COL7A1 gene which inhibits the production of Type VII collagen. 

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 30, 2023, there are 16 investigational drugs for the COL7A1 target, including 8 indications, 19 R&D institutions involved, with related clinical trials reaching 20, and as many as 599 patents.

The development of Prademagene zamikeracel represents a significant advancement in the field of biomedicine, particularly in the treatment of rare genetic disorders. If approved, this gene and cell therapy drug has the potential to provide a much-needed therapeutic option for patients with Epidermolysis Bullosa Dystrophica, improving their quality of life and potentially reducing the burden of long-term complications associated with the disease.

A screenshot of a cell phone

Description automatically generated

What are FLT3 inhibitors and how do you quickly get the latest development progress?
What are FLT3 inhibitors and how do you quickly get the latest development progress?
1 December 2023
FLT3 inhibitors are drugs that competitively inhibit the ATP binding site in the FLT3 receptor, leading to cell cycle arrest and differentiation.
Read →
Cadonilimab, a PD-1/CTLA-4 bispecific antibody, met its primary endpoint by halting progression in a Phase III recurrent/metastatic cervical cancer trial
Latest Hotspot
3 min read
Cadonilimab, a PD-1/CTLA-4 bispecific antibody, met its primary endpoint by halting progression in a Phase III recurrent/metastatic cervical cancer trial
1 December 2023
In the Phase III trial for the initial treatment of recurrent/metastatic cervical cancer in all types of patients, Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) has achieved the primary goal of halting disease progression.
Read →
Exploring Tebotelimab 's R&D successes and its clinical results at the 2023 AACR
Exploring Tebotelimab 's R&D successes and its clinical results at the 2023 AACR
1 December 2023
New clinical results for Tebotelimab, a PD-1/LAG-3 dual antibody, shown at 2023 AACR, reveal promise for untreated advanced mucosal melanoma.
Read →
Gracell Biotechnologies announces FDA clearance for a Phase 1/2 trial of FasTCAR-T GC012F for treatment-resistant Systemic Lupus Erythematosus
Latest Hotspot
3 min read
Gracell Biotechnologies announces FDA clearance for a Phase 1/2 trial of FasTCAR-T GC012F for treatment-resistant Systemic Lupus Erythematosus
1 December 2023
Gracell Biotechnologies reveals FDA approval for a Phase 1/2 Clinical Trial IND application concerning FasTCAR-T GC012F, aimed at treating stubborn Systemic Lupus Erythematosus.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.